Karyopharm Therapeutics (NASDAQ:KPTI) has been on my watch list since 2017 but the conditions have never manifested or I always found a way to talk myself out of taking the leap and establishing a position. However, I have moved KPTI
Karyopharm Therapeutics: After Years Of Waiting I'm Ready To Join The Bulls
Summary
- Karyopharm Therapeutics has been on my watch list for several years. Sadly, my buy conditions never manifested for me to establish a position. Now I am looking for an entry.
- I believe Karyopharm’s current valuation along with its upside potential will eventually bring in some buyers at these levels and hopefully inject some bullish sentiment around the ticker.
- I discuss my strategy for entering KPTI and how I plan on managing that position while we wait for some of the potent near-term catalysts.
Biologics is a full-time healthcare investor who developed a passion for biotech and life saving therapies after working in the medical field for years. His trade focus is around innovative companies developing breakthrough therapies and/or pharmaceuticals with catalysts for potential acquisitions.
He is the leader of the investing group Compounding Healthcare. Features of the group include: Several model healthcare portfolios, a weekly newsletter, a daily watchlist, and chat for dialogue and questions. Learn more.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in KPTI over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.